ID24240A - Senyawa piperidinilaminometil triflorometil eter siklus sebagai bahan antagonis p - Google Patents

Senyawa piperidinilaminometil triflorometil eter siklus sebagai bahan antagonis p

Info

Publication number
ID24240A
ID24240A IDW20000926A ID20000926A ID24240A ID 24240 A ID24240 A ID 24240A ID W20000926 A IDW20000926 A ID W20000926A ID 20000926 A ID20000926 A ID 20000926A ID 24240 A ID24240 A ID 24240A
Authority
ID
Indonesia
Prior art keywords
piperidinylaminomethy
antagonic
trifloromethyl
eter
cycle
Prior art date
Application number
IDW20000926A
Other languages
English (en)
Indonesian (id)
Inventor
Kunio Satake
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ID24240A publication Critical patent/ID24240A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW20000926A 1997-11-19 1998-10-26 Senyawa piperidinilaminometil triflorometil eter siklus sebagai bahan antagonis p ID24240A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9701466 1997-11-19

Publications (1)

Publication Number Publication Date
ID24240A true ID24240A (id) 2000-07-13

Family

ID=11004634

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000926A ID24240A (id) 1997-11-19 1998-10-26 Senyawa piperidinilaminometil triflorometil eter siklus sebagai bahan antagonis p

Country Status (39)

Country Link
US (2) US20030208079A1 (sr)
EP (1) EP1032571B1 (sr)
JP (2) JP3394239B2 (sr)
KR (1) KR100366902B1 (sr)
CN (1) CN1173974C (sr)
AP (1) AP909A (sr)
AR (1) AR016422A1 (sr)
AT (1) ATE219078T1 (sr)
AU (1) AU734218B2 (sr)
BG (1) BG63969B1 (sr)
CA (1) CA2310627C (sr)
CO (1) CO4771153A1 (sr)
CZ (1) CZ297315B6 (sr)
DE (1) DE69806045T2 (sr)
DK (1) DK1032571T3 (sr)
DZ (1) DZ2655A1 (sr)
EA (1) EA002621B1 (sr)
ES (1) ES2177058T3 (sr)
HR (1) HRP20000313B1 (sr)
HU (1) HUP0101112A3 (sr)
ID (1) ID24240A (sr)
IL (1) IL135631A0 (sr)
IS (1) IS2202B (sr)
MA (1) MA26567A1 (sr)
MY (1) MY120558A (sr)
NO (2) NO20002544L (sr)
NZ (1) NZ503912A (sr)
OA (1) OA11380A (sr)
PA (1) PA8463001A1 (sr)
PE (1) PE20000021A1 (sr)
PL (1) PL193484B1 (sr)
PT (1) PT1032571E (sr)
RS (1) RS49792B (sr)
SK (1) SK283460B6 (sr)
TN (1) TNSN98210A1 (sr)
TR (1) TR200001463T2 (sr)
TW (1) TW426667B (sr)
UA (1) UA59417C2 (sr)
WO (1) WO1999025714A1 (sr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812617D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
HRP20010821A2 (en) * 1999-05-06 2002-12-31 Pfizer Prod Inc Substituted benzolactam compounds
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
EP1178984B1 (en) * 1999-05-21 2003-03-19 Pfizer Products Inc. 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
WO2001025233A1 (en) * 1999-10-07 2001-04-12 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives
EP1095939B1 (en) * 1999-10-18 2004-01-07 Pfizer Products Inc. Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
ES2266416T3 (es) 2001-08-30 2007-03-01 Pfizer Products Inc. Procedimiento para la preparacion de compuestos 2-(4-alquil-1-piperazinil)-benzaldehido y compuestos de -bencilidenilo por sustitucion nucleofila aromatica de 2-fluorobenzaldehido con 4-alquil-1-piperazina en agua como solvente.
US20040001895A1 (en) * 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
CA2496447A1 (en) * 2002-08-27 2004-03-11 Mark L. Witten Amelioration of effects of cigarette smoke
US6911544B2 (en) * 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
DE102008000891A1 (de) 2008-03-31 2009-10-01 Robert Bosch Gmbh Schutzsystem für Werkzeugmaschinen
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
EP3758688B1 (en) 2018-02-26 2024-03-27 Ospedale San Raffaele S.r.l. Nk-1 antagonists for use in the treatment of ocular pain
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
KR19980703354A (ko) * 1995-03-27 1998-10-15 나카토미히로타카 피페리딘 유도체
TW475930B (en) * 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
JP3042894B2 (ja) * 1995-07-07 2000-05-22 ファイザー製薬株式会社 サブスタンスｐアンタゴニストとしての置換ベンゾラクタム化合物
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
US6329396B1 (en) * 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
EP1178984B1 (en) * 1999-05-21 2003-03-19 Pfizer Products Inc. 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
EP1095939B1 (en) * 1999-10-18 2004-01-07 Pfizer Products Inc. Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds

Also Published As

Publication number Publication date
JP2003040777A (ja) 2003-02-13
CO4771153A1 (es) 1999-04-30
NO20002544L (no) 2000-07-17
SK283460B6 (sk) 2003-08-05
KR100366902B1 (ko) 2003-01-09
HUP0101112A2 (hu) 2002-05-29
CN1279681A (zh) 2001-01-10
EA002621B1 (ru) 2002-06-27
AP909A (en) 2000-12-04
PL340642A1 (en) 2001-02-12
WO1999025714A1 (en) 1999-05-27
MA26567A1 (fr) 2004-12-20
AR016422A1 (es) 2001-07-04
TNSN98210A1 (fr) 2005-03-15
HK1033313A1 (en) 2001-08-24
DK1032571T3 (da) 2002-07-15
NZ503912A (en) 2002-09-27
HRP20000313A2 (en) 2000-12-31
PE20000021A1 (es) 2000-02-25
US20050171354A1 (en) 2005-08-04
DE69806045D1 (en) 2002-07-18
ES2177058T3 (es) 2002-12-01
YU29400A (sh) 2003-02-28
BG63969B1 (bg) 2003-08-29
PA8463001A1 (es) 2000-09-29
AU734218B2 (en) 2001-06-07
CZ297315B6 (cs) 2006-11-15
TR200001463T2 (tr) 2000-12-21
BG104437A (en) 2001-02-28
EP1032571A1 (en) 2000-09-06
HUP0101112A3 (en) 2002-06-28
AU9454998A (en) 1999-06-07
PL193484B1 (pl) 2007-02-28
EA200000432A1 (ru) 2000-12-25
AP9801402A0 (en) 1998-12-31
IS5470A (is) 2000-04-26
EP1032571B1 (en) 2002-06-12
MY120558A (en) 2005-11-30
JP3394239B2 (ja) 2003-04-07
JP2001523680A (ja) 2001-11-27
IL135631A0 (en) 2001-05-20
CA2310627C (en) 2005-08-09
RS49792B (sr) 2008-06-05
ATE219078T1 (de) 2002-06-15
DE69806045T2 (de) 2002-11-14
TW426667B (en) 2001-03-21
UA59417C2 (uk) 2003-09-15
CZ20001834A3 (cs) 2001-07-11
NO20002544D0 (no) 2000-05-18
OA11380A (en) 2004-01-27
DZ2655A1 (fr) 2003-03-22
CA2310627A1 (en) 1999-05-27
SK7232000A3 (en) 2001-09-11
NO20042879L (no) 2000-07-17
CN1173974C (zh) 2004-11-03
PT1032571E (pt) 2002-09-30
IS2202B (is) 2007-02-15
US20030208079A1 (en) 2003-11-06
HRP20000313B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
ID24372A (id) SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs
FI960156A7 (fi) Bentsyylioksikinuklidiinit aineet P antagonisteina
MA24035A1 (fr) Formulations injectables de quinolones
EE200000321A (et) Uudsed ühendid
ID22641A (id) Proses pembuatan e-kaprolaktam
NO20001728D0 (no) Fremgangsmåte for fremstilling av chirale forbindelser
IS2202B (is) Píperidínýlamínómetýl tríflúormetýl sýklísk eter efnasambönd sem efnis P mótlyf
ID19754A (id) Metode untuk memproduksi formal siklik secara kontinyu
ID22840A (id) Proses untuk penyiapan komposisi aspal
NO20023937L (no) Fremgangsmåte for fremstilling av substituert tiazolidindion
ID24527A (id) Proses pembuatan senyawa-senyawa farmasi
NO20001777L (no) Fremgangsmate for fremstilling av substituerte 4-fenyl-4-cyanocykloheksankarboksylsyrer
ID24327A (id) Produksi senyawa-senyawa avermektin
NO996432L (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
ID22430A (id) Proses pembuatan senyawa-senyawa benzotiazolona
ID23410A (id) Senyawa-senyawa amonium kuaterner sebagai antagonis tacikinin
ATE289195T1 (de) Verwendung von substituierten 4-amino-1- phenylbutan-2-ol-verbindungen als arzneimittel
NO980316D0 (no) Fremgangsmåte for fremstilling av polymerisater av N-vinylkarprolaktam
ID24733A (id) Proses pembuatan paroksetin hidroklorida
ID19763A (id) Proses produksi bahan organik butiran
NO20003077D0 (no) FremgangsmÕte for fremstilling av klorbenzooksazolen
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner
NO982975L (no) FremgangsmÕte for fremstilling av fosfatbundne keramer
NO20002476L (no) FremgangsmÕte for fremstilling av formylimidazoler
ID27627A (id) Proses pembuatan senyawa-senyawa eter siklik piperidinilaminometil trifluorometil